An interventional study of portable air filtration systems in Exposure to Toxic Dust and Elevated Blood Lead Levels, sponsored by Michigan State University. Recruiting at 1 site in United States. Open to participants aged Up to 7 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Michigan State University · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this study is to assess the effectiveness of portable air filtration (PAF) for mitigating lead dust exposures and reducing childhood blood lead levels in older housing.
In close collaboration with local health departments, this project will enroll 40 participants who (1) reside in housing built before 1970, and (2) have children under six years of age with blood lead levels (BLL) >5 μg/dL. Specific objectives include (1) assess reduction of Pb dust exposure via the intervention, (2) assess the ability of PAF to reduce childhood BLL indirectly via reductions in Pb dust exposure, and (3) develop evidence-based exposure reduction guidance for wider public use of PAF. The project team will measure Pb levels in (1) suspended dust, (2) floor dust, and (3) children's blood before the start and finish of the two-month-long intervention as well as at the midpoint.
Michigan State University is the lead sponsor of 143 studies on the registry; 27 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Portable air filtration units will be kept running in homes for two months.
Other: portable air filtration systems
Two portable air filtration units placed in subjects' homes (one in child's bedroom and one in living room) will be kept running for two months.
Change in blood lead level
change in blood lead level (in ug/dL).
Time frame: After two months at the end of the intervention
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2022 to primary completion in Jul 2026, 43 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.